Which shoulder options could help you?

How do I calm a shoulder flare?

Reduce the repeated motion that raised the soreness. You don't need to guard the arm all day. Gentle use can help it stay loose.

Keep your movement below sharp pain. The soreness shouldn't keep climbing afterward. If it does, use less force next time.

Night pain can make the day harder. Try sleeping away from the sore side. Support your arm in a relaxed position.

How does strength work help?

Four small muscles hold the arm in its socket. That steady hold helps larger muscles lift your arm. Weakness makes common tasks feel harder.

Start with movement that doesn't cause sharp pain. The soreness shouldn't rise after you stop. A physical therapist can set a safe range.

Progress may show up in small ways. Reaching a shelf may feel steadier. You may sleep longer before the ache wakes you.

What can an office offer besides surgery?

An exam can separate stiffness from tendon weakness. Tendons are cords connecting muscles to bones. It'll also check whether neck pain travels downward.

QC Kinetix offers non-surgical shoulder options Gilbert residents can discuss, including PRP and concentrated PRP. PRP is a blood portion spun to collect more platelets. Platelets are tiny blood parts used in care meant to support repair.

Concentrated PRP gathers a larger share of platelets. The prepared blood portion is used for your sore shoulder. It doesn't promise new tissue or certain relief.

Surgery still helps some serious damage. A fresh tear with weakness may need review. Severe joint wear may lead there too.

Sources

1. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

2. The August 2025 AAOS Evidence-Based Clinical Practice Guideline on Management of Rotator Cuff Injuries issued 25 recommendations and 4 consensus statements. Among its updates it clearly RESTRICTS the use of platelet-rich plasma and marrow stimulation in rotator cuff repair, limits prolotherapy in full-thickness tears, establishes CT as an adjunctive imaging modality, and endorses early mobilization after repair of small-to-medium tears.

   Ye Y, et al. — [Interpretation of the 2025 American Academy of Orthopaedic Surgeons (AAOS) on Management of Rotator Cuff Injuries Evidence-Based Clinical Practice Guideline].. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2026. DOI: 10.7507/1002-1892.202511084.

3. A 2025 systematic review of 1,125 patients receiving intra-articular injections for glenohumeral osteoarthritis reported a 7.2% overall complication rate and a 3.2% rate of proceeding to surgery. Hyaluronic acid showed consistent though modest benefit, while the evidence for ORTHOBIOLOGICS (PRP, bone marrow aspirate concentrate, mesenchymal stem cells) 'remains limited', mainly because of heterogeneity in design, outcomes and patient characteristics.

   Migliorini F, et al. — Intra-articular injections for shoulder arthritis in adults: a systematic review.. Eur J Med Res, 2025. DOI: 10.1186/s40001-025-03423-4.

4. The evidence overview underpinning the 2020 EULAR recommendations on intra-articular therapies pooled 29 quality-appraised systematic reviews. Hyaluronic acid showed a small effect on pain and function in KNEE OA but not in hip OA or shoulder capsulitis; intra-articular glucocorticoid showed small effects in knee OA and on function in hip OA and shoulder capsulitis; PRP showed benefit in knee OA but NOT in hip OA, and mesenchymal stem cells behaved similarly. Overall conclusion: most intra-articular therapies exert SMALL effects and are well tolerated.

   Rodriguez-García SC, et al. — Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews.. RMD open, 2021. DOI: 10.1136/rmdopen-2021-001658.

5. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing, topical NSAIDs, oral NSAIDs and intra-articular glucocorticoid injection in knee OA. Notably it does NOT strongly recommend any biologic injectable.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & rheumatology (Hoboken, N.J.), 2020. DOI: 10.1002/art.41142.

6. The Cochrane review of exercise for knee osteoarthritis found high-quality evidence that land-based therapeutic exercise provides short-term benefit in pain and physical function, sustained for at least 2-6 months after the programme ends, with mild transient soreness the only reported adverse effect across 45 trials. It is the best-evidenced treatment for this condition and it costs nothing per injection.

   Fransen M, et al. — Exercise for osteoarthritis of the knee.. The Cochrane database of systematic reviews, 2015. DOI: 10.1002/14651858.CD004376.pub3.

7. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.